JNJ-26483327
| CAS No. | 807640-87-5 | Cat. No. | BCP28258 |
| Name | JNJ-26483327 | ||
| Synonyms | JNJ26483327; JNJ 26483327; BGB102; BGB-102; BGB 102; | ||
| Formula | C22H25BrN4O2 | M. Wt | 457.36 |
| Description | JNJ-26483327, also known as BGB102, is an orally bioavailable, small-molecule, multitargeted reversible tyrosine kinase inhibitor with potential antineoplastic activity. Multitargeted tyrosine kinase inhibitor JNJ-26483327 binds to and inhibits several members of the epidermal growth factor receptor (EGFR) family, including EGFR, HER2 and HER4; Src family kinases (Lyn, Yes, Fyn, Lck and Src); and vascular endothelial growth factor receptor type 3 (VEGFR3). | ||
| Pathways | Angiogenesis/Protein Tyrosine Kinase Jak/Stat Pathway | ||
| Targets | EGFR | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.